Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

11.6%

88 terminated/withdrawn out of 758 trials

Success Rate

82.3%

-4.2% vs industry average

Late-Stage Pipeline

33%

250 trials in Phase 3/4

Results Transparency

61%

252 of 410 completed trials have results

Key Signals

140 recruiting252 with results63 terminated25 withdrawn

Enrollment Performance

Analytics

Phase 2
204(30.7%)
Phase 1
200(30.1%)
Phase 3
178(26.8%)
Phase 4
72(10.8%)
N/A
8(1.2%)
Early Phase 1
3(0.5%)
665Total
Phase 2(204)
Phase 1(200)
Phase 3(178)
Phase 4(72)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (758)

Showing 20 of 758 trials
NCT07271186Phase 2Recruiting

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Role: lead

NCT05097287Phase 4Active Not Recruiting

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Role: collaborator

NCT06672237Phase 3Recruiting

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Role: collaborator

NCT05648214Phase 1Recruiting

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Role: lead

NCT06836609Phase 1Recruiting

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Role: lead

NCT05704634Phase 1Active Not Recruiting

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Role: collaborator

NCT04701983Phase 3Completed

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Role: collaborator

NCT06379789Phase 1Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Role: lead

NCT04751487Phase 3Completed

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Role: collaborator

NCT07455851Phase 1Recruiting

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT06931717Phase 3Recruiting

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Role: collaborator

NCT07316114Recruiting

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

Role: collaborator

NCT07154745Phase 3Recruiting

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Role: lead

NCT07527910Phase 2Not Yet Recruiting

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Role: lead

NCT07216066Phase 1Recruiting

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

Role: lead

NCT07527923Phase 1Not Yet Recruiting

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Role: lead

NCT06865339Phase 2Recruiting

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT05983068Phase 4Active Not Recruiting

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

Role: collaborator

NCT05955508Phase 2Active Not Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Role: lead

NCT06975787Phase 1Recruiting

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Role: lead